Cisplatin: mode of cytotoxic action and molecular basis of resistance
The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ATM kinase seems to be activated primarily in response to the induction of double-strand breaks whereas ATR is critical for cellular checkpoint responses to stalled replication forks and to many types of DNA damage, such as those induced by UV light and cisplatin (16,17).”
In the citing paper
“Clinical use of cisplatin is complicated by the dose-limiting side effects as well as rapid development of drug resistance [5].”
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“A major factor affecting the loss of apoptotic function is p53 gene mutation (see Figure 6), which is observed in about a half of all cancers (Hollstein et al., 1991; Soussi, 2000).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 2×
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“…resistance-associated (MRP) gene family, composed of at least seven members (MRP1–7), has been a major target of investigations, primarily as several of these ABC membrane proteins have been found in tumor cells and associated with cellular efflux of a variety of drugs (Borst et al., 2000).”
Background
Research works printed but not linked: 5
- Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943. · doi:10.1182/blood.v90.3.935.935_935_943 · Paper page
- Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.
- He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.
- Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100. · doi:10.1002/(sici)1097-0215(19980703)77:1<94::aid-ijc15>3.0.co;2-9
- Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.
Cited by
Items 601–700 of 1,004
Wang, C., Song, X., Chen, L., & Xiao, Y. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.11.018 · Cited by 68
Zaltariov, M., Hammerstad, M., Arabshahi, H. J., Jovanović, K., Richter, K. W., Cazacu, M., Shova, S. G., Bălan, M., Andersen, N. H., Radulovic, S. S., et al. (2017) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.6b03178 · Cited by 66
Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents
Thiabaud, G., He, G., Sen, S., Shelton, K. A., Baze, W. B., Segura, L. J., Alaniz, J., Macias, R. M., Lyness, G., Watts, A. B., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914911117 · Cited by 67
“This translates to an overall 45% 5-y survival rate (5).”
BackgroundSelf-citationFransson, Å., Glaessgen, D., Alfredsson, J., Wiman, K. G., Bajalica-Lagercrantz, S., & Mohell, N. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0239-6 · Cited by 65
“Platinum-based drugs have for decades been used for effective treatment of many solid tumors, including ovarian cancer [25, 26].”
BackgroundWang, J., Nie, J.-J., Guo, P., Yan, Z., Yu, B., & Bu, W. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11013 · Cited by 66
Ruiz de Porras, V., Font, A., & Aytes, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.033 · Cited by 65
Dharmasivam, M., Gurumoorthy, P., Gunasekaran, K., Kumar, R. S., & Rahiman, A. K. (2015) · New Journal of Chemistry · doi:10.1039/c5nj01059d · Cited by 66
Sears, C. R., & Turchi, J. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.344911 · Cited by 65
Preparation and cytotoxicity of cisplatin-containing liposomes
Júnior, Á. D. C., Vieira, F. P., Melo, V. J. D., Lopes, M. T. P., Silveira, J. N., Ramaldes, G. A., Garnier‐Suillerot, A., Pereira-Maia, E. C., & Oliveira, M. C. (2007) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006005000125 · Cited by 65
Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Yee-Lin, V., Pooi-Fong, W., & Soo-Beng, A. K. (2018) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557517666170717125821 · Cited by 65
“Furthermore, the emergence of chemo-resistance remains as major obstacle for cisplatin-based chemotherapy which impaired cisplatin-induced apoptosis [44].”
BackgroundIwasa, T., Okamoto, I., Takezawa, K., Yamanaka, K., Nakahara, T., Kita, A., Koutoku, H., Sasamata, M., Hatashita, E., Yamada, Y., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605713 · Cited by 70
Dinuclear Ruthenium(II) Complexes That Induce and Stabilise G‐Quadruplex DNA
Xu, L., Chen, X., Wu, J., Wang, J., Ji, L., & Chao, H. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201405991 · Cited by 64
Role of long non‐coding RNA in drug resistance in non‐small cell lung cancer
Wang, L., Ma, L., Xu, F., Zhai, W., Dong, S., Yin, L., Liu, J., & Yu, Z. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12652 · Cited by 65
Triggering endogenous Z-RNA sensing for anti-tumor therapy through ZBP1-dependent necroptosis
Yang, T., Wang, G., Zhang, M., Hu, X., Li, Q., Yun, F., Xing, Y., Song, X., Zhang, H., Hu, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113377 · Cited by 66
Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells
Wu, Z., Lu, H., & Chao, C. C. ‐. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.029 · Cited by 63
Synergistic effect of rapamycin and cisplatin in endometrial cancer cells
Bae-Jump, V. L., Zhou, C., Boggess, J. F., & Gehrig, P. A. (2009) · Cancer · doi:10.1002/cncr.24431 · Cited by 67
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer
Abdel-Fatah, T. M. A., Sultana, R., Abbotts, R., Hawkes, C., Seedhouse, C., Chan, S. Y. T., & Madhusudan, S. (2012) · International Journal of Cancer · doi:10.1002/ijc.27980 · Cited by 64
Teng, P.-N., Wang, G., Hood, B. L., Conrads, K. A., Hamilton, C. A., Maxwell, G. L., Darcy, K. M., & Conrads, T. P. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.687 · Cited by 66
“DNA repair capacity and modulation of apoptosis evasion mechanisms (Siddik, 2003; Galluzzi et al, 2012).”
BackgroundInfluentialCarlo, F. D., Witte, T. R., Hardman, W. E., & Claudio, P. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069760 · Cited by 69
Suh, D. H., Kim, H. S., Kim, B., & Song, Y. S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.08.011 · Cited by 69
Lee, J. G., & Wu, R. (2015) · Neoplasia · doi:10.1016/j.neo.2014.12.008 · Cited by 68
“[19] Siddik ZH (2003).”
BackgroundThe PDGFRβ–AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors
Juliachs, M., Muñoz, C., Moutinho, C., Vidal, A., Condom, E., Esteller, M., Graupera, M., Casanovas, O., Germà, J. R., Villanueva, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1131 · Cited by 64
“org Clin Cancer Res; 20(3) February 1, 2014 665”
BackgroundInfluentialVajpayee, V., Song, Y. H., Jung, Y. J., Kang, S. C., Kim, H., Kim, I. S., Wang, M., Cook, T. R., Stang, P. J., & Chi, K. (2012) · Dalton Transactions · doi:10.1039/c2dt11811d · Cited by 64
Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
Thakkar, A., Wang, B., Picon‐Ruiz, M., Buchwald, P., & Ince, T. A. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3807-y · Cited by 68
“Since many chemotherapeutic agents induce G2/M arrest followed by apoptosis [43, 44], we examined whether combining DHT”
BackgroundSOX9 is targeted for proteasomal degradation by the E3 ligase FBW7 in response to DNA damage
Hong, X., Liu, W., Song, R., Shah, J. J., Feng, X., Tsang, C. K., Morgan, K. M., Bunting, S. F., Inuzuka, H., Zheng, X., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw748 · Cited by 68
Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy
Reeßing, F., & Szymański, W. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160906103223 · Cited by 71
Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node?
Oun, R., & Rowan, E. G. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.063 · Cited by 68
Synergistic anti‐tumor effect of paclitaxel with CRM197, an inhibitor of HB‐EGF, in ovarian cancer
Yagi, H., Yotsumoto, F., Sonoda, K., Kuroki, M., Mekada, E., & Miyamoto, S. (2008) · International Journal of Cancer · doi:10.1002/ijc.24031 · Cited by 66
Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments
Cirri, D., Bartoli, F., Pratesi, A., Baglini, E., Barresi, E., & Marzo, T. (2021) · Biomedicines · doi:10.3390/biomedicines9050504 · Cited by 71
“Indeed, the commonly recognized mechanism for the anticancer action of cisplatin relies on the activation occurring through the release of the chloride ligands, with subsequent coordination at the level of the nuclear DNA, which eventually triggers apoptosis [15].”
BackgroundProtective Effect of Natural Antioxidants on Reducing Cisplatin-Induced Nephrotoxicity
Zhou, J., Nie, R., Yin, Y., Cai, X., Xie, D., & Cai, M. (2022) · Disease Markers · doi:10.1155/2022/1612348 · Cited by 86
“Mildly damaged DNA can be repaired whereas extensive DNA damage can lead to the irreversible injury and cell death, which is the fundamental mechanism of cisplatin’s cytotoxic antitumor activity in cancer therapy; proliferating cancer cells are sensitive to DNA damage especially [11, 12].”
BackgroundChemotherapeutic drugs induced female reproductive toxicity and treatment strategies
Bhardwaj, J. K., Bikal, P., & Sachdeva, S. N. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23371 · Cited by 79
Ramos-Lima, F. J., Quiroga, A. G., Serelde, B. G., Blanco, F. F., Carnero, A., & Navarro‐Ranninger, C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061219c · Cited by 63
Phenethyl isothiocyanate sensitizes human cervical cancer cells to apoptosis induced by cisplatin
Wang, X., Govind, S., Sajankila, S. P., Mi, L., Roy, R., & Chung, F. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201000560 · Cited by 66
Sato, T., Suzuki, M., Sato, Y., Echigo, S., & Rikiishi, H. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.5.1233 · Cited by 66
Wiedemeyer, W. R., Beach, J. A., & Karlan, B. Y. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00034 · Cited by 71
“Upon entering a cell, platinum-based compounds generate inter- and intra-strand DNA adducts that activate the DNA damage response (DDR) and subsequently induce DNA repair (13).”
BackgroundLaPensee, E. W., Schwemberger, S. J., LaPensee, C. R., Bahassi, E. M., Afton, S. E., & Ben‐Jonathan, N. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp120 · Cited by 63
Eisenberg, M. C., & Jain, H. V. (2017) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2017.07.018 · Cited by 79
“From G1/S, cells re-enter G2/M on completion of DNA synthesis.”
BackgroundInfluentialThe effects of Curcuma longa and curcumin on reproductive systems
Mohebbati, R., Anaeigoudari, A., & Khazdair, M. R. (2017) · Endocrine Regulations · doi:10.1515/enr-2017-0024 · Cited by 75
“Th e protective eff ect of p53, a tumor suppressor protein, against cancer has been well documented. p53 has been exhibited to involve in the cytotoxic action of chemotherapeutic drugs on cancer cells (Zunino et al. 1997; Siddik 2003).”
BackgroundHong, W., Cai, P., Xu, C., Cao, D., Yu, W., Zhao, Z., Huang, M., & Jin, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00043 · Cited by 70
“However, one of the main factors contributing to the failure of this chemotherapy regimen is the development of drug resistance, which affects the prognosis and survival of the patients (Siddik, 2003).”
BackgroundMukherjee, A., Huynh, V., Gaines, K., Reh, W. A., & Vásquez, K. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0542 · Cited by 65
Arnold, N. B., Ketterer, K., Kleeff, J., Friess, H., Büchler, M. W., & Korc, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2999 · Cited by 63
Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells
Fujiwara, M., Izuishi, K., Sano, T., Hossain, M. A., Kimura, S., Masaki, T., & Suzuki, Y. (2008) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-27-76 · Cited by 63
Li, M., Lin, A., Luo, P., Shen, W., Xiao, D., Gou, L., Zhang, J., & Guo, L. (2020) · Aging · doi:10.18632/aging.102683 · Cited by 62
Atomic force microscopy—A tool for structural and translational DNA research
Main, K. H. S., Provan, J. I., Haynes, P. J., Wells, G., Hartley, J. A., & Pyne, A. L. B. (2021) · APL Bioengineering · doi:10.1063/5.0054294 · Cited by 76
Oxaliplatin-induced hepatic sinusoidal obstruction syndrome
Chen, Z., Ren, X., Liu, D., & Zhang, C. (2021) · Toxicology · doi:10.1016/j.tox.2021.152882 · Cited by 70
ATP11B mediates platinum resistance in ovarian cancer
Moreno-Smith, M., Halder, J. B., Meltzer, P. S., Gonda, T. A., Mangala, L. S., Rupaimoole, R., Lu, C., Nagaraja, A. S., Gharpure, K. M., Kang, Y., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65425 · Cited by 62
“The molecular mechanisms of resistance to cisplatin can be broadly divided into 2 main groups: (a) mechanisms that reduce cisplatin accumulation and, thereby, attenuate DNA damage and (b) mechanisms that inhibit propagation of cisplatin-mediated DNA damage signaling to the apoptotic machinery (3).”
BackgroundSelf-citationTohamy, A. A., Abdella, E. M., Ahmed, R. R., & Ahmed, Y. K. (2013) · Cytotechnology · doi:10.1007/s10616-013-9568-0 · Cited by 64
“CDDP is an inorganic platinum compound with a broad spectrum anti-neoplastic activity against different types of human tumors (Siddik 2003).”
BackgroundMalandrino, P., Al Ghuzlan, A., Castaing, M., Young, J., Caillou, B., Travagli, J.-P., Elias, D., de Baere, T., Dromain, C., Paci, A., et al. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0341 · Cited by 62
Current View in Platinum Drug Mechanisms of Peripheral Neurotoxicity
Chiorazzi, A., Semperboni, S., & Marmiroli, P. (2015) · Toxics · doi:10.3390/toxics3030304 · Cited by 68
“(GpG) cross-links and monofunctional adducts make up about 2%–6% of the platinum bound to DNA each [26].”
BackgroundInfluentialKim, Y., Jang, M., Lim, S., Won, H., Yoon, K., Park, J., Kim, H. J., Kim, B., Park, W.-S., Ha, J., et al. (2011) · Hepatology · doi:10.1002/hep.24539 · Cited by 70
Moreira‐Pais, A., Ferreira, R. M., & da Costa, R. M. G. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.010 · Cited by 74
Ibrahim, A., Al-Hizab, F. A., Abushouk, A. I., & Abdel‐Daim, M. M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01268 · Cited by 68
“Moreover, cisplatin directly interacts with glutathione (GSH), suppressing its antioxidant effect (Arany and Safirstein, 2003; Siddik, 2003).”
BackgroundDolgova, N. V., Nokhrin, S. M., Yu, C. H., George, G. N., & Dmitriev, O. Y. (2013) · Biochemical Journal · doi:10.1042/bj20121656 · Cited by 66
Wolters, D. A., Stefanopoulou, M., Dyson, P. J., & Groessl, M. (2012) · Metallomics · doi:10.1039/c2mt20070h · Cited by 62
Papadaki, C., Sfakianaki, M., Lagoudaki, E. D., Giagkas, G., Ioannidis, G., Trypaki, M., Tsakalaki, E., Voutsina, A., Koutsopoulos, A. V., Mavroudis, D., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.492 · Cited by 65
“Decreased membrane transport, increased cytoplasmic detoxification, increased DNA repair activity and increased tolerance to DNA damage are the major mechanisms that can contribute to cisplatin resistance (Siddik, 2003; Kelland, 2007).”
BackgroundFunctional TauT Protects Against Acute Kidney Injury
Han, X., Yue, J., & Chesney, R. W. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008050465 · Cited by 61
Robust Structure and Reactivity of Aqueous Arsenous Acid–Platinum(II) Anticancer Complexes
Miodragović, Ð., Quentzel, J. A., Kurutz, J. W., Stern, C. L., Ahn, R. W., Kandela, I. K., Mazar, A. P., & O’Halloran, T. V. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201303251 · Cited by 65
Overcoming tumor resistance to cisplatin by cationic lipid-assisted prodrug nanoparticles
Cao, Z., Chen, Z., Sun, C., Li, H., Wang, H., Cheng, Q., Zuo, Z.-Q., Wang, J., Liu, Y., Wang, Y., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.001 · Cited by 63
Chang, C., Wang, Y., Zalath, M. B., Liu, D., Cardillo, T. M., & Goldenberg, D. M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0219 · Cited by 62
“Thus, despite the notable success in treating diverse cancers, chemotherapeutics, including antibody–drug conjugates (ADC), lose clinical activity over time, as exemplified by irinotecan (4), doxorubicin (5), paclitaxel (6), cisplatin (7), gemtuzumab ozogamicin (8), inotuzumab ozogamicin (9), and others (1).”
BackgroundAlam, M., Kashyap, T., Pramanik, K. K., Singh, A. K., Nagini, S., & Mishra, R. (2017) · Clinical Oral Investigations · doi:10.1007/s00784-017-2074-6 · Cited by 62
MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1
Liu, Y., Niu, Z., Lin, X., & Tian, Y. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.6 · Cited by 62
Guerra, F., Paiano, A., Migoni, D., Girolimetti, G., Perrone, A. M., Iaco, P. D., Fanizzi, F. P., Gasparre, G., & Bucci, C. (2019) · Cancers · doi:10.3390/cancers11010052 · Cited by 67
“The main obstacle to an effective reduction of toxicity and resistance is the complexity, and the still limited knowledge, of uptake, efflux, trafficking and mechanisms of biodistribution and action of CDDP and platinum derivatives [1,3].”
BackgroundLanvers‐Kaminsky, C., Krefeld, B., Dinnesen, A. G., Deuster, D., Seifert, E., Würthwein, G., Jaehde, U., Pieck, A. C., & Boos, J. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20673 · Cited by 61
RhoGTPases – A novel link between cytoskeleton organization and cisplatin resistance
Mokady, D., & Meiri, D. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.01.001 · Cited by 65
“The best-studied mode of action is the induction of interand intra-strand DNA cross-linking, through the formation of DNA-platinum adducts that activate apoptotic signal transduction pathways, resulting in cell death (Siddik, 2003).”
Abdel‐Daim, M. M., Abdel-Rahman, H. G., Dessouki, A. A., El‐Far, A. H., Khodeer, D. M., Bin-Jumah, M. N., Alhader, M. S., Alkahtani, S. H., & Aleya, L. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.136338 · Cited by 62
“Moreover, ROS induce cell necrosis by promoting cell membrane lipid peroxidation, protein alkylation, and DNA damage (Atessahin et al., 2005).”
BackgroundInfluentialMelanoma therapeutics: a literature review
Dhanyamraju, P. K., & Patel, T. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20210163 · Cited by 76
“One of the routinely used BCT procedures involves the use of Vinblastine, which targets microtubules[181] while Cisplatin enhances DNA damage[182] with IFN-α 2b or IL-2 as the immunotherapy.”
MethodA platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
Fronik, P., Gutmann, M., Vician, P., Stojanovic, M., Kastner, A., Heffeter, P., Pirker, C., Keppler, B. K., Berger, W., & Kowol, C. R. (2022) · Communications Chemistry · doi:10.1038/s42004-022-00661-z · Cited by 63
JWA reverses cisplatin resistance via the CK2—XRCC1 pathway in human gastric cancer cells
Xu, W., Chen, Q., Wang, Q., Sun, Y., Wang, S., Li, A., Xu, S., Røe, O. D., Wang, M., Zhang, R., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.517 · Cited by 63
“mechanisms to overcome cisplatin-induced DNA damage and apoptosis, and lead to cisplatin resistance.(5,6) Two of the”
BackgroundRNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells
Arora, S., Bisanz, K. M., Peralta, L. A., Basu, G. D., Choudhary, A. K., Tibes, R., & Azorsa, D. O. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.006 · Cited by 64
Zhou, Y., Chen, Q., Qin, R., Zhang, K., & Li, H. (2014) · Tumor Biology · doi:10.1007/s13277-014-2551-3 · Cited by 63
López-Flores, A., Jurado, R., & García‐López, P. (2005) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2005.06.005 · Cited by 60
Zhang, Y., & Shen, X. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2090 · Cited by 60
Zajac, J., Kostrhunová, H., Novohradský, V., Vrána, O., Raveendran, R., Gibson, D., Kašpárková, J., & Brabec, V. (2015) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2015.12.003 · Cited by 60
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
Pan, C., Chang, Y.-F., Lee, M.-S., Wen, B.-C., Ko, J., Liang, S., & Liang, M. (2016) · BMC Cancer · doi:10.1186/s12885-016-2888-7 · Cited by 62
“Cisplatin interacts with DNA to form DNA intrastrand crosslink adducts, inducing apoptotic cell death [30].”
Wu, G., Cao, L., Zhu, J., Tan, Z., Tang, M., Li, Z., Hu, Y., Yu, R., Zhang, S., Song, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2554 · Cited by 60
“Formation andpersistence ofDNAadducts ofCDDPare vital in inducing apoptosis (33).”
BackgroundLow GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer
Fang, X., Zhong, G., Wang, Y., Lin, Z., Lin, R., & Yao, T. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2735-2 · Cited by 63
ATP11B mediates platinum resistance in ovarian cancer
Moreno-Smith, M., Halder, J. B., Meltzer, P. S., Gonda, T. A., Mangala, L. S., Rupaimoole, R., Lu, C., Nagaraja, A. S., Gharpure, K. M., Kang, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122301 · Cited by 59
Self-citationMethylation-mediated gene silencing as biomarkers of gastric cancer: A review
Nakamura, J., Tanaka, T., Kitajima, Y., Noshiro, H., & Miyazaki, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.11991 · Cited by 64
Yu, Z., Cao, W., Ren, Y., Zhang, Q., & Liu, J. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.19 · Cited by 62
Strategies for the Nuclear Delivery of Metal Complexes to Cancer Cells
Huynh, M., Vinck, R., Gibert, B., & Gasser, G. (2024) · Advanced Materials · doi:10.1002/adma.202311437 · Cited by 64
The soluble metal-binding domain of the copper transporter ATP7B binds and detoxifies cisplatin
Dolgova, N. V., Olson, D., Lutsenko, S., & Dmitriev, O. Y. (2009) · Biochemical Journal · doi:10.1042/bj20081359 · Cited by 61
The Effects of GLUT1 on the Survival of Head and Neck Squamous Cell Carcinoma
Li, S., Yang, X., Wang, P., & Ran, X. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000354466 · Cited by 63
Non-apoptotic programmed cell death induced by a copper(II) complex in human fibrosarcoma cells
Tardito, S., Bussolati, O., Gaccioli, F., Gatti, R., Guizzardi, S., Uggeri, J., Marchiò, L., Lanfranchi, M., & Franchi‐Gazzola, R. (2006) · Histochemistry and Cell Biology · doi:10.1007/s00418-006-0183-4 · Cited by 65
Möller, M., Herzer, K., Wenger, T., Herr, I., & Wink, M. (2007) · Oncology Reports · doi:10.3892/or.18.3.737 · Cited by 59
Cisplatin Carbonato Complexes. Implications for Uptake, Antitumor Properties, and Toxicity
Centerwall, C. R., Goodisman, J., Kerwood, D. J., & Dabrowiak, J. C. (2005) · Journal of the American Chemical Society · doi:10.1021/ja053353c · Cited by 60
Carreira, M., Calvo-Sanjuán, R., Sanaú, M., Zhao, X., Magliozzo, R. S., Marzo, I., & Contel, M. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.017 · Cited by 59
Das, R., Bhattacharya, K., Samanta, S. K., Pal, B. C., & Mandal, C. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.005 · Cited by 61
“The treatment of cervical cancer with cisplatin is linked with its concentration-limiting toxicity [4,5] whereas mahanine is reported to be nontoxic up to 150 mg/kg body weight of normal mice [15,17].”
BackgroundВладимирович, Х. А., Иванова, Ф. Г., Moisseev, A., Khokhrin, D. V., Sleptsova, Y., Gorbunova, V. A., & Limborska, S. (2012) · Pharmacogenomics · doi:10.2217/pgs.11.140 · Cited by 61
Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer
Tian, Y., Wu, K., Liu, Q., Han, N., Zhang, L., Chu, Q., & Chen, Y. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0311-0 · Cited by 63
“Platinum-based drugs are defined as DNA adduct-forming agents that exert antineoplastic effects by inducing the formation of double-stranded DNA cross-links, thus resulting in irreversible DNA damage [9].”
BackgroundDyshlovoy, S. A., Madanchi, R., Hauschild, J., Otte, K., Alsdorf, W. H., Schumacher, U., Kalinin, V. I., Silchenko, A. S., Avilov, S. A., Honecker, F. U., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3085-z · Cited by 61
“In contrast, cisplatin directly targets DNA by the induction of crosslinks (which is usually associated with the strong activation of p21 expression) [35], and therefore can be considered a “strong stimulus” activating the pro-apoptotic functions of p53.”
BackgroundLiu, C.-W., Hua, K.-T., Li, K.-C., Kao, H.-F., Hong, R.-L., Ko, J.-Y., Hsiao, M., Kuo, M.-L., & Tan, C.-T. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0567-t · Cited by 58
“The mechanisms involved in acquired cisplatin resistance are reducing drug accumulation, elevating cisplatin metabolism, and enhancing DNA damage repair (12, 13).”
BackgroundCarbon nanotube capsules enhance the in vivo efficacy of cisplatin
Guven, A., Villares, G. J., Hilsenbeck, S. G., Lewis, A. N., Landua, J. D., Dobrolecki, L. E., Wilson, L. J., & Lewis, M. T. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.04.035 · Cited by 59
Meng, H., Wang, K., Chen, X., Guan, X., Hu, L., Xiong, G., Li, J., & Bai, Y. (2015) · PubMed · Cited by 64
Huh, H.-C., Lee, S., Lee, S.-K., Park, N. H., & Han, I. (2011) · Nutrition and Cancer · doi:10.1080/01635581.2011.607548 · Cited by 59
Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics
Korzhnev, D. M., & Hadden, M. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00596 · Cited by 58
DNA methylation changes in epithelial ovarian cancer histotypes
Earp, M. A., & Cunningham, J. M. (2015) · Genomics · doi:10.1016/j.ygeno.2015.09.001 · Cited by 68
“ed into DNA, inducing formation of adducts and eliciting mismatch repair which, in turn, activates apoptosis [73].”
Chen, J., Lan, T., Hou, J., Zhang, J., An, Y., Tie, L., Pan, Y., Liu, J., & Li, X. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.01.015 · Cited by 64
Lee, H. W., Choi, Y.-W., Han, J. H., Kim, J., Jung, J. H., Jeong, S. H., Kang, S. Y., Choi, J., Oh, Y. T., Park, K. J., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2008.12.005 · Cited by 59
Polymorphic Transporters and Platinum Pharmacodynamics
Sprowl, J. A., Ness, R. A., & Sparreboom, A. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rv-073 · Cited by 69
Natural compounds to overcome cancer chemoresistance: toxicological and clinical issues
Turrini, E., Ferruzzi, L., & Fimognari, C. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.972933 · Cited by 62
Metadata
- Authors
- Siddik, Z. H.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Siddik, Zahid H
- ORCID
- Siddik, Zahid H
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7265-7279
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2164277862
- Cited by
- 3,335
- References
- 154
- Citations by year
- 2026: 67 · 2025: 94 · 2024: 127 · 2023: 161 · 2022: 195 · 2021: 216 · 2020: 203 · 2019: 181 · 2018: 184 · 2017: 185 · 2016: 215 · 2015: 193 · 2014: 205 · 2013: 175 · 2012: 165
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca077332-03)
- National Cancer Institute (CA-77332, R01CA082361, CA 82361)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin, cisplatin resistance, DNA adducts, DNA cross-linking, apoptosis, ATR signaling, p53, p73, MAPK signaling, DNA damage response, drug uptake, drug inactivation, DNA repair, HER2/neu, PI3K/Akt signaling, Bcl-2, caspase activation, signal transduction
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, Humans, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.